Clinical Trial: A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Advanced Hepatocellular Carcinoma
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma
Brief Summary:
This study will be conducted in 2 parts.The first part is a phase 1 single-agent dose escalation,optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.
Read more